Recent advances with liposomes as drug carriers for treatment of neurodegenerative diseases
A major challenge in treating neurogenerative diseases is delivering drugs across the blood–brain barrier (BBB). In this review, we summarized the development of liposome-based drug delivery system with enhanced BBB penetration for efficient brain drug delivery. We focused on the liposome-based ther...
Saved in:
| Published in | Biomedical engineering letters Vol. 11; no. 3; pp. 211 - 216 |
|---|---|
| Main Authors | , |
| Format | Journal Article |
| Language | English |
| Published |
Korea
The Korean Society of Medical and Biological Engineering
01.08.2021
Springer Nature B.V 대한의용생체공학회 |
| Subjects | |
| Online Access | Get full text |
| ISSN | 2093-9868 2093-985X 2093-985X |
| DOI | 10.1007/s13534-021-00198-5 |
Cover
Loading…
| Abstract | A major challenge in treating neurogenerative diseases is delivering drugs across the blood–brain barrier (BBB). In this review, we summarized the development of liposome-based drug delivery system with enhanced BBB penetration for efficient brain drug delivery. We focused on the liposome-based therapeutics targeting Alzheimer's disease and Parkinson's disease because they are most common types of adult chronic neurodegenerative disorders. A variety of liposome with surface modification of BBB-targeting ligands have been created to cross the BBB via transcytosis to the therapeutic efficacy of Alzheimer’s disease and Parkinson’s disease drugs. Recent advances in liposome are providing alternatives to overcome BBB for more efficient therapeutic strategy. To improve the BBB penetration of liposomes, we need to completely understand the pathophysiological changes at the BBB. |
|---|---|
| AbstractList | A major challenge in treating neurogenerative diseases is delivering drugs across the blood–brain barrier (BBB). In this review, we summarized the development of liposome-based drug delivery system with enhanced BBB penetration for efficient brain drug delivery. We focused on the liposome-based therapeutics targeting Alzheimer's disease and Parkinson's disease because they are most common types of adult chronic neurodegenerative disorders. A variety of liposome with surface modification of BBB-targeting ligands have been created to cross the BBB via transcytosis to the therapeutic efficacy of Alzheimer’s disease and Parkinson’s disease drugs. Recent advances in liposome are providing alternatives to overcome BBB for more efficient therapeutic strategy. To improve the BBB penetration of liposomes, we need to completely understand the pathophysiological changes at the BBB. A major challenge in treating neurogenerative diseases is delivering drugs across the blood–brain barrier (BBB). In thisreview, we summarized the development of liposome-based drug delivery system with enhanced BBB penetration for effi cientbrain drug delivery. We focused on the liposome-based therapeutics targeting Alzheimer’s disease and Parkinson’s diseasebecause they are most common types of adult chronic neurodegenerative disorders. A variety of liposome with surfacemodifi cation of BBB-targeting ligands have been created to cross the BBB via transcytosis to the therapeutic effi cacy ofAlzheimer’s disease and Parkinson’s disease drugs. Recent advances in liposome are providing alternatives to overcome BBBfor more effi cient therapeutic strategy. To improve the BBB penetration of liposomes, we need to completely understand thepathophysiological changes at the BBB. KCI Citation Count: 0 A major challenge in treating neurogenerative diseases is delivering drugs across the blood-brain barrier (BBB). In this review, we summarized the development of liposome-based drug delivery system with enhanced BBB penetration for efficient brain drug delivery. We focused on the liposome-based therapeutics targeting Alzheimer's disease and Parkinson's disease because they are most common types of adult chronic neurodegenerative disorders. A variety of liposome with surface modification of BBB-targeting ligands have been created to cross the BBB via transcytosis to the therapeutic efficacy of Alzheimer's disease and Parkinson's disease drugs. Recent advances in liposome are providing alternatives to overcome BBB for more efficient therapeutic strategy. To improve the BBB penetration of liposomes, we need to completely understand the pathophysiological changes at the BBB.A major challenge in treating neurogenerative diseases is delivering drugs across the blood-brain barrier (BBB). In this review, we summarized the development of liposome-based drug delivery system with enhanced BBB penetration for efficient brain drug delivery. We focused on the liposome-based therapeutics targeting Alzheimer's disease and Parkinson's disease because they are most common types of adult chronic neurodegenerative disorders. A variety of liposome with surface modification of BBB-targeting ligands have been created to cross the BBB via transcytosis to the therapeutic efficacy of Alzheimer's disease and Parkinson's disease drugs. Recent advances in liposome are providing alternatives to overcome BBB for more efficient therapeutic strategy. To improve the BBB penetration of liposomes, we need to completely understand the pathophysiological changes at the BBB. |
| Author | Park, Tae-Eun Seo, Min-Wook |
| Author_xml | – sequence: 1 givenname: Min-Wook surname: Seo fullname: Seo, Min-Wook organization: Department of Biomedical Engineering, Ulsan National Institute of Science and Technology – sequence: 2 givenname: Tae-Eun orcidid: 0000-0003-3979-5405 surname: Park fullname: Park, Tae-Eun email: tepark@unist.ac.kr organization: Department of Biomedical Engineering, Ulsan National Institute of Science and Technology |
| BackLink | https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART002756006$$DAccess content in National Research Foundation of Korea (NRF) |
| BookMark | eNp9kU9rFTEUxQep2Fr7BVwNuNHFaP7MzWQ2QilWCwWhVBBchEzm5jXtTPJMZp747Zt5UxW7aDZJyPmd3HvPy-LAB49F8ZqS95SQ5kOiHHhdEUYrQmgrK3hWHDHS8qqV8P3g71nIw-IkpVuSF1BoOX9RHPKaAyG1PCp-XKFBP5W632lvMJW_3HRTDm4bUhjzVaeyj_OmNDpGhzGVNsRyiqinccGCLT3OMfS4QY9RT26HZe8S6oTpVfHc6iHhycN-XHw7_3R99qW6_Pr54uz0sjK1hKmqQVPbGd00kknORE9F3YFEYRstsCEAtrNto2sQkgnRWCtNx9Bo5DVBBvy4eLf6-mjVnXEqaLffN0HdRXV6dX2h8iAYA5q1H1ftdu5G7Jfeox7UNrpRx9978v8X726yz05JTgVQlg3ePhjE8HPGNKnRJYPDoD2GOSkGIGsgDZVZ-uaR9DbM0edRLCoQIBhfqperysSQUkSrjJvyIMPyvxsUJWoJXK2Bqxy42geuFpQ9Qv_08STEVyhlsd9g_FfVE9Q9Mwq-8Q |
| CitedBy_id | crossref_primary_10_1002_slct_202301626 crossref_primary_10_1002_advs_202403219 crossref_primary_10_3390_jnt4030010 crossref_primary_10_1016_j_biopha_2022_113492 crossref_primary_10_1016_j_mtbio_2023_100913 crossref_primary_10_3390_biom13071085 crossref_primary_10_3390_ijms25179690 crossref_primary_10_3390_ijms222212309 crossref_primary_10_1021_acschemneuro_2c00202 crossref_primary_10_3390_cells12232669 crossref_primary_10_1038_s41401_021_00846_7 crossref_primary_10_1016_j_vibspec_2023_103510 crossref_primary_10_1016_j_brainresbull_2022_09_017 crossref_primary_10_1016_j_ccr_2024_215926 crossref_primary_10_2174_0929867330666221115103513 crossref_primary_10_2174_1566523222666220328142427 crossref_primary_10_3389_fmedt_2024_1367521 crossref_primary_10_3390_ijms222111859 crossref_primary_10_1016_j_arr_2024_102394 crossref_primary_10_2174_1567201820666230523114259 crossref_primary_10_2174_2468187313666230228102211 crossref_primary_10_32947_ajps_v25i1_1065 crossref_primary_10_3390_molecules29081774 |
| Cites_doi | 10.1016/j.nano.2014.09.015 10.3390/pharmaceutics10030128 10.2147/IJN.S132472 10.1016/j.jconrel.2018.03.019 10.1186/s12645-019-0055-y 10.1016/j.biomaterials.2016.07.027 10.1016/j.biomaterials.2014.03.082 10.2147/IJN.S183117 10.1038/s41467-018-07882-8 10.1021/mp200129p 10.1080/10717544.2019.1636420 10.1056/NEJM2003ra020003 10.1016/j.jconrel.2016.05.044 10.1016/j.ejpb.2020.01.005 10.1021/acsami.6b15831 10.1038/s41596-018-0066-x 10.3389/fnins.2018.01019 10.2174/138161211797440221 10.1016/j.jconrel.2017.05.019 10.3389/fneur.2019.00218 10.2174/156802609787521571 10.2217/nnm-2016-0267 10.1021/acschemneuro.6b00042 10.2147/IJN.S239608 10.1021/acssuschemeng.8b04507 10.7150/thno.21254 10.1016/j.ijpharm.2013.05.009 10.1080/21688370.2015.1138017 10.1242/dmm.030205 10.1126/science.1067568 10.1038/s41380-020-0742-4 |
| ContentType | Journal Article |
| Copyright | Korean Society of Medical and Biological Engineering 2021 Korean Society of Medical and Biological Engineering 2021. |
| Copyright_xml | – notice: Korean Society of Medical and Biological Engineering 2021 – notice: Korean Society of Medical and Biological Engineering 2021. |
| DBID | AAYXX CITATION 7X8 5PM ACYCR |
| DOI | 10.1007/s13534-021-00198-5 |
| DatabaseName | CrossRef MEDLINE - Academic PubMed Central (Full Participant titles) Korean Citation Index |
| DatabaseTitle | CrossRef MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Engineering |
| EISSN | 2093-985X |
| EndPage | 216 |
| ExternalDocumentID | oai_kci_go_kr_ARTI_9862251 PMC8316512 10_1007_s13534_021_00198_5 |
| GrantInformation_xml | – fundername: Ministry of Health and Welfare grantid: HU20C0094; HU20C0094 funderid: http://dx.doi.org/10.13039/501100003625 – fundername: Ulsan National Institute of Science and Technology grantid: 1.200094.01 funderid: http://dx.doi.org/10.13039/501100002613 – fundername: ; grantid: 1.200094.01 – fundername: ; grantid: HU20C0094; HU20C0094 |
| GroupedDBID | -EM 0R~ 0VY 203 29~ 2VQ 30V 4.4 406 408 53G 8TC 96X AAAVM AACDK AAHNG AAIAL AAJBT AAJKR AANZL AARHV AARTL AASML AATNV AATVU AAUYE AAWCG AAYIU AAYQN AAYTO AAYZH AAZMS ABAKF ABDZT ABECU ABFTV ABJNI ABJOX ABKCH ABMQK ABQBU ABSXP ABTEG ABTHY ABTKH ABTMW ABXPI ACAOD ACDTI ACGFS ACHSB ACIWK ACKNC ACMLO ACOKC ACPIV ACPRK ACZOJ ADHHG ADHIR ADINQ ADKNI ADKPE ADRFC ADTPH ADURQ ADYFF ADZKW AEBTG AEFQL AEGNC AEJHL AEJRE AEMSY AEOHA AEPYU AESKC AETCA AEVLU AEXYK AFBBN AFLOW AFQWF AFWTZ AFZKB AGAYW AGDGC AGJBK AGMZJ AGQEE AGQMX AGRTI AGWZB AGYKE AHAVH AHBYD AHKAY AHSBF AHYZX AIAKS AIGIU AIIXL AILAN AITGF AJBLW AJRNO AKLTO ALFXC ALMA_UNASSIGNED_HOLDINGS AMKLP AMXSW AMYLF AMYQR AUKKA AXYYD AYJHY BGNMA CSCUP DNIVK DPUIP EBLON EBS EIOEI EJD ESBYG FERAY FIGPU FINBP FNLPD FRRFC FSGXE FYJPI GGCAI GGRSB GJIRD GQ6 HF~ HMJXF HRMNR HYE HZ~ I0C IKXTQ IWAJR IXD J-C JBSCW JZLTJ KOV LLZTM M4Y NPVJJ NQJWS NU0 O9- O9J OK1 PT4 RLLFE ROL RPM RSV S27 SEG SHX SISQX SJYHP SNE SNPRN SNX SOHCF SOJ SPISZ SRMVM SSLCW STPWE SZN T13 TSG U2A UG4 UOJIU UTJUX UZXMN VFIZW W48 Z7X ZMTXR ~A9 AAYXX ABBRH ABDBE ABFSG ACSTC AEZWR AFDZB AFHIU AFOHR AHPBZ AHWEU AIXLP ATHPR AYFIA CITATION ABRTQ 7X8 5PM ACYCR |
| ID | FETCH-LOGICAL-c485t-45a1fbca77828326d164b58e6f7a6e7055fbf97a45682667ff8cb2ecae340e253 |
| IEDL.DBID | U2A |
| ISSN | 2093-9868 2093-985X |
| IngestDate | Sun Mar 09 07:52:41 EDT 2025 Thu Aug 21 14:33:02 EDT 2025 Thu Sep 04 22:19:44 EDT 2025 Fri Jul 25 11:17:48 EDT 2025 Tue Jul 01 01:04:53 EDT 2025 Thu Apr 24 23:08:46 EDT 2025 Fri Feb 21 02:48:13 EST 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | false |
| IsScholarly | true |
| Issue | 3 |
| Keywords | Liposome Parkinson's disease Alzheimer's disease Blood–brain barrier |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c485t-45a1fbca77828326d164b58e6f7a6e7055fbf97a45682667ff8cb2ecae340e253 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Review-3 content type line 23 |
| ORCID | 0000-0003-3979-5405 |
| OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/8316512 |
| PMID | 34350048 |
| PQID | 2555656235 |
| PQPubID | 2043953 |
| PageCount | 6 |
| ParticipantIDs | nrf_kci_oai_kci_go_kr_ARTI_9862251 pubmedcentral_primary_oai_pubmedcentral_nih_gov_8316512 proquest_miscellaneous_2558450718 proquest_journals_2555656235 crossref_citationtrail_10_1007_s13534_021_00198_5 crossref_primary_10_1007_s13534_021_00198_5 springer_journals_10_1007_s13534_021_00198_5 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2021-08-01 |
| PublicationDateYYYYMMDD | 2021-08-01 |
| PublicationDate_xml | – month: 08 year: 2021 text: 2021-08-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | Korea |
| PublicationPlace_xml | – name: Korea – name: Heidelberg |
| PublicationTitle | Biomedical engineering letters |
| PublicationTitleAbbrev | Biomed. Eng. Lett |
| PublicationYear | 2021 |
| Publisher | The Korean Society of Medical and Biological Engineering Springer Nature B.V 대한의용생체공학회 |
| Publisher_xml | – name: The Korean Society of Medical and Biological Engineering – name: Springer Nature B.V – name: 대한의용생체공학회 |
| References | Ball, Teo, Chandra, Chapman (CR26) 2019; 10 Ordóñez-Gutiérrez, Re, Bereczki, Ioja, Gregori, Andersen (CR23) 2015; 11 Qu, Lin, He, Wang, Fu, Zhang (CR27) 2018; 277 Wang, Li, Zhang, Liu, Zhu, Liu (CR30) 2018; 6 Clark, Kodadek (CR4) 2016; 7 Saraiva, Praça, Ferreira, Santos, Ferreira, Bernardino (CR5) 2016; 235 Agrawal, Tripathi, Saraf, Saraf, Antimisiaris, Mourtas (CR13) 2017; 260 Ross, Taylor, Fullwood, Allsop (CR17) 2018; 13 Yang, Zhang, Wang, Wu, Lou, Qi (CR22) 2013; 452 Piazzini, Landucci, Graverini, Pellegrini-Giampietro, Bilia, Bergonzi (CR16) 2018; 10 DeMattos, Bales, Cummins, Paul, Holtzman (CR24) 2002; 295 Greene, Campbell (CR7) 2016; 4 Park, Mustafaoglu, Herland, Hasselkus, Mannix, FitzGerald (CR31) 2019; 10 Denora, Trapani, Laquintana, Lopedota, Trapani (CR10) 2009; 9 Kong, Li, Ni, Xiao, Yao, Wang (CR18) 2020; 15 Teixeira, Lopes, Amaral, Costa (CR2) 2020; 149 Bergmann, Lawler, Qu, Fadzen, Wolfe, Regan (CR32) 2018; 13 Zheng, Ma, Bai, Yang, Xu (CR14) 2015; 8 Dong (CR11) 2018; 8 Kuo, Wang (CR19) 2014; 35 CR28 Nussbaum, Ellis (CR3) 2003; 348 Pulgar (CR6) 2019; 12 Tang, Wang, Yan, Chu, Yang, Song (CR20) 2019; 26 Ji, Wang, Gao, Xing, Li, Liu (CR29) 2017; 12 Mahringer, Ott, Reimold, Reichel, Fricker (CR8) 2011; 17 Shawahna, Uchida, Decleves, Ohtsuki, Yousif, Dauchy (CR9) 2011; 8 Gitler, Dhillon, Shorter (CR1) 2017; 10 Ordonez-Gutierrez, Posado-Fernandez, Ahmadvand, Lettiero, Wu, Anton (CR25) 2017; 112 Beltrán-Gracia, López-Camacho, Higuera-Ciapara, Velázquez-Fernández, Vallejo-Cardona (CR12) 2019; 10 Chen, Duan, Yuan, Li, Pang, Liang (CR15) 2017; 9 Kuo, Tsao (CR21) 2017; 12 VM Pulgar (198_CR6) 2019; 12 A Mahringer (198_CR8) 2011; 17 Z-Z Yang (198_CR22) 2013; 452 198_CR28 LF Clark (198_CR4) 2016; 7 N Ball (198_CR26) 2019; 10 T-E Park (198_CR31) 2019; 10 C Ross (198_CR17) 2018; 13 N Denora (198_CR10) 2009; 9 MI Teixeira (198_CR2) 2020; 149 RL Nussbaum (198_CR3) 2003; 348 M Qu (198_CR27) 2018; 277 S Bergmann (198_CR32) 2018; 13 C Chen (198_CR15) 2017; 9 S Tang (198_CR20) 2019; 26 C Zheng (198_CR14) 2015; 8 L Ordóñez-Gutiérrez (198_CR23) 2015; 11 E Beltrán-Gracia (198_CR12) 2019; 10 RB DeMattos (198_CR24) 2002; 295 AD Gitler (198_CR1) 2017; 10 Y-C Kuo (198_CR21) 2017; 12 L Ordonez-Gutierrez (198_CR25) 2017; 112 B Ji (198_CR29) 2017; 12 C Greene (198_CR7) 2016; 4 M Agrawal (198_CR13) 2017; 260 R Shawahna (198_CR9) 2011; 8 C Saraiva (198_CR5) 2016; 235 X Dong (198_CR11) 2018; 8 V Piazzini (198_CR16) 2018; 10 Y-C Kuo (198_CR19) 2014; 35 M Wang (198_CR30) 2018; 6 L Kong (198_CR18) 2020; 15 |
| References_xml | – volume: 11 start-page: 421 year: 2015 end-page: 430 ident: CR23 article-title: Repeated intraperitoneal injections of liposomes containing phosphatidic acid and cardiolipin reduce amyloid-β levels in APP/PS1 transgenic mice publication-title: Nanomedicine doi: 10.1016/j.nano.2014.09.015 – volume: 10 start-page: 128 year: 2018 ident: CR16 article-title: Stealth and cationic nanoliposomes as drug delivery systems to increase andrographolide BBB permeability publication-title: Pharmaceutics doi: 10.3390/pharmaceutics10030128 – volume: 12 start-page: 2857 year: 2017 ident: CR21 article-title: Neuroprotection against apoptosis of SK-N-MC cells using RMP-7-and lactoferrin-grafted liposomes carrying quercetin publication-title: Int J Nanomed doi: 10.2147/IJN.S132472 – volume: 277 start-page: 173 year: 2018 end-page: 182 ident: CR27 article-title: A brain targeting functionalized liposomes of the dopamine derivative N-3, 4-bis (pivaloyloxy)-dopamine for treatment of Parkinson's disease publication-title: J Control Release doi: 10.1016/j.jconrel.2018.03.019 – volume: 10 start-page: 1 year: 2019 end-page: 40 ident: CR12 article-title: Nanomedicine review: clinical developments in liposomal applications publication-title: Cancer Nanotechnol doi: 10.1186/s12645-019-0055-y – volume: 112 start-page: 141 year: 2017 end-page: 152 ident: CR25 article-title: ImmunoPEGliposome-mediated reduction of blood and brain amyloid levels in a mouse model of Alzheimer's disease is restricted to aged animals publication-title: Biomaterials doi: 10.1016/j.biomaterials.2016.07.027 – volume: 35 start-page: 5954 year: 2014 end-page: 5964 ident: CR19 article-title: Protection of SK-N-MC cells against β-amyloid peptide-induced degeneration using neuron growth factor-loaded liposomes with surface lactoferrin publication-title: Biomaterials doi: 10.1016/j.biomaterials.2014.03.082 – volume: 13 start-page: 8507 year: 2018 ident: CR17 article-title: Liposome delivery systems for the treatment of Alzheimer’s disease publication-title: Int J Nanomed doi: 10.2147/IJN.S183117 – volume: 10 start-page: 1 year: 2019 end-page: 12 ident: CR31 article-title: Hypoxia-enhanced blood–brain barrier chip recapitulates human barrier function and shuttling of drugs and antibodies publication-title: Nat Commun doi: 10.1038/s41467-018-07882-8 – volume: 8 start-page: 1332 year: 2011 end-page: 1341 ident: CR9 article-title: Transcriptomic and quantitative proteomic analysis of transporters and drug metabolizing enzymes in freshly isolated human brain microvessels publication-title: Mol Pharm doi: 10.1021/mp200129p – volume: 26 start-page: 700 year: 2019 end-page: 707 ident: CR20 article-title: Brain-targeted intranasal delivery of dopamine with borneol and lactoferrin co-modified nanoparticles for treating Parkinson’s disease publication-title: Drug Deliv doi: 10.1080/10717544.2019.1636420 – volume: 348 start-page: 1356 year: 2003 end-page: 1364 ident: CR3 article-title: Alzheimer's disease and Parkinson's disease publication-title: N Engl J Med doi: 10.1056/NEJM2003ra020003 – volume: 235 start-page: 34 year: 2016 end-page: 47 ident: CR5 article-title: Nanoparticle-mediated brain drug delivery: overcoming blood–brain barrier to treat neurodegenerative diseases publication-title: J Control Release doi: 10.1016/j.jconrel.2016.05.044 – volume: 149 start-page: 192 year: 2020 end-page: 217 ident: CR2 article-title: Current insights on lipid nanocarrier-assisted drug delivery in the treatment of neurodegenerative diseases publication-title: Eur J Pharm Biopharm doi: 10.1016/j.ejpb.2020.01.005 – volume: 9 start-page: 5864 year: 2017 end-page: 5873 ident: CR15 article-title: Peptide-22 and cyclic RGD functionalized liposomes for glioma targeting drug delivery overcoming BBB and BBTB publication-title: ACS Appl Mater Interfaces doi: 10.1021/acsami.6b15831 – volume: 8 start-page: 1658 year: 2015 ident: CR14 article-title: Transferrin and cell-penetrating peptide dual-functioned liposome for targeted drug delivery to glioma publication-title: Int J Clin Exp Med – volume: 13 start-page: 2827 year: 2018 end-page: 2843 ident: CR32 article-title: Blood–brain-barrier organoids for investigating the permeability of CNS therapeutics publication-title: Nat Protoc doi: 10.1038/s41596-018-0066-x – volume: 12 start-page: 1019 year: 2019 ident: CR6 article-title: Transcytosis to cross the blood brain barrier, new advancements and challenges publication-title: Front Neurosci doi: 10.3389/fnins.2018.01019 – volume: 17 start-page: 2762 year: 2011 end-page: 2770 ident: CR8 article-title: The ABC of the blood–brain barrier—regulation of drug efflux pumps publication-title: Curr Pharm Des doi: 10.2174/138161211797440221 – volume: 260 start-page: 61 year: 2017 end-page: 77 ident: CR13 article-title: Recent advancements in liposomes targeting strategies to cross blood–brain barrier (BBB) for the treatment of Alzheimer's disease publication-title: J Control Release doi: 10.1016/j.jconrel.2017.05.019 – volume: 10 start-page: 218 year: 2019 ident: CR26 article-title: Parkinson's disease and the environment publication-title: Front Neurol doi: 10.3389/fneur.2019.00218 – volume: 9 start-page: 182 year: 2009 end-page: 196 ident: CR10 article-title: Recent advances in medicinal chemistry and pharmaceutical technology-strategies for drug delivery to the brain publication-title: Curr Top Med Chem doi: 10.2174/156802609787521571 – volume: 12 start-page: 237 year: 2017 end-page: 253 ident: CR29 article-title: Combining nanoscale magnetic nimodipine liposomes with magnetic resonance image for Parkinson's disease targeting therapy publication-title: Nanomedicine doi: 10.2217/nnm-2016-0267 – volume: 7 start-page: 520 year: 2016 end-page: 527 ident: CR4 article-title: The immune system and neuroinflammation as potential sources of blood-based biomarkers for Alzheimer’s disease, Parkinson’s disease, and Huntington’s disease publication-title: ACS Chem Neurosci doi: 10.1021/acschemneuro.6b00042 – volume: 15 start-page: 2841 year: 2020 ident: CR18 article-title: Transferrin-modified osthole PEGylated liposomes travel the blood–brain barrier and mitigate Alzheimer’s disease-related pathology in APP/PS-1 Mice publication-title: Int J Nanomed doi: 10.2147/IJN.S239608 – volume: 6 start-page: 17124 year: 2018 end-page: 17133 ident: CR30 article-title: Magnetic resveratrol liposomes as a new theranostic platform for magnetic resonance imaging guided Parkinson’s disease targeting therapy publication-title: ACS Sustain Chem Eng doi: 10.1021/acssuschemeng.8b04507 – volume: 8 start-page: 1481 year: 2018 ident: CR11 article-title: Current strategies for brain drug delivery publication-title: Theranostics doi: 10.7150/thno.21254 – volume: 452 start-page: 344 year: 2013 end-page: 354 ident: CR22 article-title: Enhanced brain distribution and pharmacodynamics of rivastigmine by liposomes following intranasal administration publication-title: Int J Pharm doi: 10.1016/j.ijpharm.2013.05.009 – volume: 4 start-page: e1138017 year: 2016 ident: CR7 article-title: Tight junction modulation of the blood brain barrier: CNS delivery of small molecules publication-title: Tissue Barriers doi: 10.1080/21688370.2015.1138017 – volume: 10 start-page: 499 year: 2017 end-page: 502 ident: CR1 article-title: Neurodegenerative disease: models, mechanisms, and a new hope publication-title: Dis Model Mech. doi: 10.1242/dmm.030205 – ident: CR28 – volume: 295 start-page: 2264 year: 2002 end-page: 2267 ident: CR24 article-title: Brain to plasma amyloid-β efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease publication-title: Science doi: 10.1126/science.1067568 – volume: 15 start-page: 2841 year: 2020 ident: 198_CR18 publication-title: Int J Nanomed doi: 10.2147/IJN.S239608 – volume: 112 start-page: 141 year: 2017 ident: 198_CR25 publication-title: Biomaterials doi: 10.1016/j.biomaterials.2016.07.027 – volume: 295 start-page: 2264 year: 2002 ident: 198_CR24 publication-title: Science doi: 10.1126/science.1067568 – volume: 149 start-page: 192 year: 2020 ident: 198_CR2 publication-title: Eur J Pharm Biopharm doi: 10.1016/j.ejpb.2020.01.005 – volume: 277 start-page: 173 year: 2018 ident: 198_CR27 publication-title: J Control Release doi: 10.1016/j.jconrel.2018.03.019 – volume: 7 start-page: 520 year: 2016 ident: 198_CR4 publication-title: ACS Chem Neurosci doi: 10.1021/acschemneuro.6b00042 – volume: 26 start-page: 700 year: 2019 ident: 198_CR20 publication-title: Drug Deliv doi: 10.1080/10717544.2019.1636420 – volume: 12 start-page: 237 year: 2017 ident: 198_CR29 publication-title: Nanomedicine doi: 10.2217/nnm-2016-0267 – volume: 10 start-page: 499 year: 2017 ident: 198_CR1 publication-title: Dis Model Mech. doi: 10.1242/dmm.030205 – volume: 8 start-page: 1332 year: 2011 ident: 198_CR9 publication-title: Mol Pharm doi: 10.1021/mp200129p – volume: 9 start-page: 182 year: 2009 ident: 198_CR10 publication-title: Curr Top Med Chem doi: 10.2174/156802609787521571 – volume: 260 start-page: 61 year: 2017 ident: 198_CR13 publication-title: J Control Release doi: 10.1016/j.jconrel.2017.05.019 – volume: 10 start-page: 1 year: 2019 ident: 198_CR31 publication-title: Nat Commun doi: 10.1038/s41467-018-07882-8 – volume: 348 start-page: 1356 year: 2003 ident: 198_CR3 publication-title: N Engl J Med doi: 10.1056/NEJM2003ra020003 – volume: 12 start-page: 1019 year: 2019 ident: 198_CR6 publication-title: Front Neurosci doi: 10.3389/fnins.2018.01019 – volume: 12 start-page: 2857 year: 2017 ident: 198_CR21 publication-title: Int J Nanomed doi: 10.2147/IJN.S132472 – volume: 9 start-page: 5864 year: 2017 ident: 198_CR15 publication-title: ACS Appl Mater Interfaces doi: 10.1021/acsami.6b15831 – volume: 6 start-page: 17124 year: 2018 ident: 198_CR30 publication-title: ACS Sustain Chem Eng doi: 10.1021/acssuschemeng.8b04507 – volume: 13 start-page: 8507 year: 2018 ident: 198_CR17 publication-title: Int J Nanomed doi: 10.2147/IJN.S183117 – volume: 8 start-page: 1658 year: 2015 ident: 198_CR14 publication-title: Int J Clin Exp Med – volume: 13 start-page: 2827 year: 2018 ident: 198_CR32 publication-title: Nat Protoc doi: 10.1038/s41596-018-0066-x – volume: 235 start-page: 34 year: 2016 ident: 198_CR5 publication-title: J Control Release doi: 10.1016/j.jconrel.2016.05.044 – volume: 10 start-page: 128 year: 2018 ident: 198_CR16 publication-title: Pharmaceutics doi: 10.3390/pharmaceutics10030128 – volume: 4 start-page: e1138017 year: 2016 ident: 198_CR7 publication-title: Tissue Barriers doi: 10.1080/21688370.2015.1138017 – volume: 8 start-page: 1481 year: 2018 ident: 198_CR11 publication-title: Theranostics doi: 10.7150/thno.21254 – volume: 452 start-page: 344 year: 2013 ident: 198_CR22 publication-title: Int J Pharm doi: 10.1016/j.ijpharm.2013.05.009 – volume: 35 start-page: 5954 year: 2014 ident: 198_CR19 publication-title: Biomaterials doi: 10.1016/j.biomaterials.2014.03.082 – volume: 11 start-page: 421 year: 2015 ident: 198_CR23 publication-title: Nanomedicine doi: 10.1016/j.nano.2014.09.015 – volume: 10 start-page: 1 year: 2019 ident: 198_CR12 publication-title: Cancer Nanotechnol doi: 10.1186/s12645-019-0055-y – ident: 198_CR28 doi: 10.1038/s41380-020-0742-4 – volume: 10 start-page: 218 year: 2019 ident: 198_CR26 publication-title: Front Neurol doi: 10.3389/fneur.2019.00218 – volume: 17 start-page: 2762 year: 2011 ident: 198_CR8 publication-title: Curr Pharm Des doi: 10.2174/138161211797440221 |
| SSID | ssj0000515933 |
| Score | 2.3171816 |
| SecondaryResourceType | review_article |
| Snippet | A major challenge in treating neurogenerative diseases is delivering drugs across the blood–brain barrier (BBB). In this review, we summarized the development... A major challenge in treating neurogenerative diseases is delivering drugs across the blood-brain barrier (BBB). In this review, we summarized the development... A major challenge in treating neurogenerative diseases is delivering drugs across the blood–brain barrier (BBB). In thisreview, we summarized the development... |
| SourceID | nrf pubmedcentral proquest crossref springer |
| SourceType | Open Website Open Access Repository Aggregation Database Enrichment Source Index Database Publisher |
| StartPage | 211 |
| SubjectTerms | Alzheimer's disease Biological and Medical Physics Biomedical Engineering and Bioengineering Biomedicine Biophysics Blood-brain barrier Drug carriers Drug delivery Drug delivery systems Engineering Liposomes Medical and Radiation Physics Movement disorders Neurodegenerative diseases Parkinson's disease Penetration Review Review Article 의공학 |
| Title | Recent advances with liposomes as drug carriers for treatment of neurodegenerative diseases |
| URI | https://link.springer.com/article/10.1007/s13534-021-00198-5 https://www.proquest.com/docview/2555656235 https://www.proquest.com/docview/2558450718 https://pubmed.ncbi.nlm.nih.gov/PMC8316512 https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART002756006 |
| Volume | 11 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| ispartofPNX | Biomedical Engineering Letters (BMEL), 2021, 11(3), , pp.211-216 |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9QwEB7R9gIHBLQVgbIyiFtrqUlsx3tcoZYCghMrterBcrz2dtU2qZLd_8-MN8myFSBxiiK_Eo8f33jG3wB8DGOJu6Dz3KkguHCF4NqhlkLahsitCk7R3eHvP9TFVHy9lJfdpbC293bvTZJxpd5cdstlLji5FBAu0VzuwJ5E3Z0c-abZZDhZoagl6xjyGarrfKyV7m7L_LmarR1pp2rCFth87Cr5yF4at6HzF_C8w49sshb4S3jiq1fw7DdWwX24RiiI9bDOvN8yOmtld4uHuq3v8dW2bNas5szZhsLVtQxxKxsczlkdWCS5nPl5pKSm9ZB1dpz2AKbnZz8_XfAuhgJ3QsslF9KmoXS2QCSAk1fNUD0qpfYqFFZ5otIJZRgXFnEUKhqqCEG7MvPO-lyc-kzmh7Bb1ZV_DawMWGosEY2jzuZtailHeuqyNCAmFCKBtO9H4zqCcYpzcWc21MjU9wb73sS-NzKB46HMw5pe45-5P6B4zK1bGGLFpue8NreNQez_xaCgcXFKEzjqpWe6-dgaVJwIuWY51vF-SMaZROYRW_l6FfNoQfBYJ1BsSX34NGp1O6Va3ERObp2nCrFTAif9-Ng0_vcfevN_2d_C0ywOXPI_PILdZbPy7xATLcsR7E0-X307G8XjqlGcEL8AUsEFWg |
| linkProvider | Springer Nature |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3Pb9MwFH5i3QE4MH5NhA0wiBt4WhLbcY_TtNGxH6dVGuJgOa5dqo5kStoLfz3vpUlLK0DaKYpiO7bzbH9f_Pw9gI-hL3EVdJ47FQQXLhNcO2QpxDZEalVwis4OX16pwVB8vZE37aGwuvN277Ykm5l6ddgtlang5FJAuERzuQXbAjm46MH20Zdv56t_KxS3ZBFFPkHCzvta6fa8zN8LWluTtooqrMHNTWfJjR3TZiE63YFh14SF_8n0YD7LD9yvDXXH-7bxKTxpkSk7WpjSM3jgi-fw-A-9whfwHUEm1o-1jgM1o7-47HZyV9blT7y1NRtV8zFztqJAeDVDRMyWruysDKyRzxz5cSN2TTMta3eI6pcwPD25Ph7wNjoDd0LLGRfSxiF3NkOMgdOCGiHxyqX2KmRWeRLpCXnoZxYRGlIYlYWgXZ54Z30qDn0i013oFWXhXwHLA-bqS8T5yAa9jS2liA9dEgdEm0JEEHffx7hWupwiaNyalegydZzBjjNNxxkZwadlnruFcMd_U3_Az26mbmJIb5uu49JMK4Os4sygAeG0F0ew31mFaUd6bZCSESZOUizj_fIxjlHaeLGFL-dNGi0IeOsIsjVrWlaN3rr-pJj8aNS-dRorRGURfO5MZvXyfzfo9f2Sv4OHg-vLC3NxdnW-B4-SxgLJy3EferNq7t8g8prlb9uB9huSIyKb |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwEB7RrYTgUJ4VKQUM4gZpm8R2vMcKWFoKFQcqFXGwHK-9rLYkqyR74dczk8dudwVIiFMU-RU7Y_sbe-YbgJd-KHAXtC600vOQ25SHyqKWQtoGT4z0VpLv8KdzeXLBP1yKy2te_I21e38l2fo0EEtTXh_Ox_5w5fiWiISHZF5AGEWFYgu2OZGzD2D7-P3Xs9U5C8UwaSPKx6i8h0MlVec78_uK1vanrbz0a9Bz03By4_a02ZRGd8D03WltUWYHizo7sD83mB7_p793YadDrOy4FbF7cMPl9-H2NR7DB_ANwSdWxjqDgorR6S67ms6LqviBr6Zi43IxYdaUFCCvYoiU2dLEnRWeNbSaYzdpSLBpBWbdzVH1EC5G7768OQm7qA2h5UrUIRcm8pk1KWIPXC7kGBWyTCgnfWqkI_Ien_lhahC5oWojU--VzWJnjUv4kYtFsguDvMjdI2CZx1JDgfgftURnIkM5oiMbRx5RKOcBRP2_0rajNKfIGld6RcZMA6dx4HQzcFoE8GpZZt4Sevw19wsUAT2zU0083PScFHpWatQ2TjUKEy6HUQD7vYTobgWoNKpqhJXjBOt4vkzGuUsXMiZ3xaLJozgBchVAuiZZy0-jVtdT8un3hgVcJZFEtBbA6158Vo3_uUN7_5b9Gdz8_HakP56enz2GW3EjgGT8uA-Duly4JwjI6uxpN-d-AalqK38 |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Recent+advances+with+liposomes+as+drug+carriers+for+treatment+of+neurodegenerative+diseases&rft.jtitle=Biomedical+engineering+letters&rft.au=Min-Wook%2C+Seo&rft.au=Park+Tae-Eun&rft.date=2021-08-01&rft.pub=Springer+Nature+B.V&rft.issn=2093-9868&rft.eissn=2093-985X&rft.volume=11&rft.issue=3&rft.spage=211&rft.epage=216&rft_id=info:doi/10.1007%2Fs13534-021-00198-5&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2093-9868&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2093-9868&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2093-9868&client=summon |